Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSumanasuriya, Semini
dc.contributor.authorSeed, George
dc.contributor.authorParr, Harry
dc.contributor.authorChristova, Rossitza
dc.contributor.authorPope, Lorna
dc.contributor.authorBertan, Claudia
dc.contributor.authorMateo Valderrama, Joaquim
dc.date.accessioned2022-03-14T13:46:05Z
dc.date.available2022-03-14T13:46:05Z
dc.date.issued2021-08
dc.identifier.citationSumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, et al. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. Eur Urol. 2021 Aug;80(2):243–53.
dc.identifier.issn0302-2838
dc.identifier.urihttps://hdl.handle.net/11351/7175
dc.descriptionCabazitaxel; ADN lliure de cèl·lules; Fracció tumoral
dc.description.sponsorshipThis work was supported by Prostate Cancer UK and the Movember Foundation through the London Movember Centre of Excellence (CEO13-2-002), Cancer Research UK (Centre Programme grant), Experimental Cancer Medicine Centre grant funding from Cancer Research UK and the Department of Health, and Biomedical Research Centre funding to the Royal Marsden ECMC (CRM064X). George Seed was funded by a Prostate Cancer UK PhD Studentship (grant ref. TLD-S15-006, 2016–2020) and a Prostate Cancer UK research fellowship (grant ref. TLD-PF19-005, from 2021). Semini Sumanasuriya was funded by a Prostate Cancer UK grant (ref. RIA1 5-ST2-O18). The authors are grateful for support and funding from Sanofi Aventis. The sponsor played a role in collection of the data and review and approval of the manuscript.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesEuropean Urology;80(2)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPròstata - Càncer - Tractament
dc.subjectElements genètics mòbils
dc.subjectPròstata - Càncer - Aspectes genètics
dc.subject.meshProstatic Neoplasms, Castration-Resistant
dc.subject.mesh/drug therapy
dc.subject.meshCirculating Tumor DNA
dc.subject.mesh/genetics
dc.titleElucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.eururo.2021.05.030
dc.subject.decsneoplasias prostáticas resistentes a la castración
dc.subject.decs/farmacoterapia
dc.subject.decsADN tumoral circulante
dc.subject.decs/genética
dc.relation.publishversionhttps://doi.org/10.1016/j.eururo.2021.05.030
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Sumanasuriya S] The Institute of Cancer Research, University of London, London, UK. The Royal Marsden Hospital, London, UK. [Seed G, Parr H, Christova R, Pope L, Bertan C] The Institute of Cancer Research, University of London, London, UK. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid34103179
dc.identifier.wos000673637600031
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple